natgillin/translations-raw huggingface dataset:
I et cross-over interaktionsstudie med blev Constella, 290 mikrogram, givet til 18 raske forsøgspersoner i 7 dage i både fastende og ikke-fastende tilstand.
In a cross-over food interaction study, 18 healthy subjects were administered Constella 290 micrograms for 7 days both in the fasting and fed state.
I et delstudie med scanning hos 153 patienter blev tegn på inflammation vurderet ved MRI ved uge 12 og udtrykt som ændring i forhold til baseline i SPARCC- (Spondyloarthritis Research Consortium of Canada) score for sacroiliacaleddene og i Berlin modifications of the ASspiMRI-a-score for rygsøjlen.
In an imaging sub-study including 153 patients, signs of inflammation were assessed by MRI at week 12 and expressed as change from baseline in SPARCC (Spondyloarthritis Research Consortium of Canada) score for sacroiliac joints and ASspiMRI-a score in the Berlin modifications for the spine.
I et diestudie på rotter: Der var minimal udskillelse af Rienso eller Rienso-deriveret radioaktivitet i mælk efter en enkelt IV administration på cirka 100 mg Fe/kg (HED på 16,1 mg Fe/kg, cirka 2 gange den anbefalede humandosis på 510 mg baseret på mg/m2) af enten det umærkede, 59Fe eller 14C- mærkede produkt til diegivende rotter 10-11 dage post partum, som toppede 8-24 timer efter administrationen.
In a lactation study in rats, there was minimal excretion of Rienso or Rienso-derived radioactivity into milk following single IV administration of approximately 100 mg Fe/kg (HED of 16.1 mg Fe/kg, approximately 2 times the recommended 510 mg human dose on a mg/m2 basis) of either the unlabelled, 59Fe or 14C-labelled product to lactating rats 10-11 days post-parturition, which peaked at 8 to 24 hours post-administration.
I et dobbelt-blindet, placebo-kontrolleret studie af patienter med ADPKD blev der indberettet et potentielt klinisk signifikant øget indhold af urinsyre (mere end 10 mg/dl) med en højere forekomst hos tolvaptan- patienter (6,2 %) sammenlignet med placebo-behandlede patienter (1,7 %).
In a double-blind, placebo-controlled trial of patients with ADPKD, potentially clinically significant increased uric acid (greater than 10 mg/dL) was reported at a higher rate in tolvaptan-patients (6.2%) compared to placebo-treated patients (1.7%).
I et dobbelt-blindet, placebo-kontrolleret studie af patienter med ADPKD blev der indberettet et potentielt klinisk signifikant øget indhold af urinsyre (mere end 10 mg/dl) med en højere forekomst hos tolvaptan-patienter (6,2 %) sammenlignet med placebo-behandlede patienter (1,7 %).
In a double-blind, placebo-controlled trial of patients with ADPKD, potentially clinically significant increased uric acid (greater than 10 mg/dL) was reported at a higher rate in tolvaptan-patients (6.2%) compared to placebo-treated patients (1.7%).
I et dobbeltblindet 12-ugers placebokontrolleret studie blev linagliptins effekt og sikkerhed undersøgt hos type 2-diabetespatienter med svært nedsat nyrefunktion, hvis samtidige baggrundsbehandling forblev uændret.
The efficacy and safety of linagliptin was also evaluated in type 2 diabetes patients with severe renal impairment in a double-blind study versus placebo for 12 weeks duration, during which background glycaemic therapies were kept stable.
I et dobbeltblindet 24-ugers studie blev virkningen og sikkerheden af linagliptin 5 mg evalueret hos ældre (> 70 år) med type 2-diabetes.
The efficacy and safety of linagliptin in elderly (age ≥ 70years) with type 2 diabetes was evaluated in a double-blind study of 24 weeks duration.
I et dobbeltblindet 24-ugers studie blev virkningen og sikkerheden af linagliptin 5 mg evalueret hos ældre (≥ 70 år) med type 2-diabetes.
The efficacy and safety of linagliptin in elderly (age ≥ 70 years) with type 2 diabetes was evaluated in a double-blind study of 24 weeks duration.
I et dobbeltblindet studie med CHB-patienter med YMDD-mutation-HBV og kompenseret leversygdom (NUC20904) og med et reduceret virologisk og biokemisk respons over for lamivudin (n=95) resulterede tilføjelse af adefovirdipivoxil 10 mg 1 gang daglig til igangværende behandling med lamivudin 100 mg i 52 uger i et gennemsnitligt fald i HBV-DNA på 4,6 log10 kopier/ml sammenlignet med en gennemsnitlig stigning på 0,3 log10 kopier/ml hos patienter, der fik lamivudin-monoterapi.
In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml compared to a median increase of 0.3 log10 copies/ml in those patients receiving lamivudine monotherapy.
I et dobbeltblindet studie med patienter med utilstrækkelig glykæmisk kontrol medførte 24 ugers behandling med begge doser empagliflozin plus linagliptin som tillæg til metforminbehandling statistisk signifikante fald (p< 0,0001) i HbA1c (ændring fra baseline på -1,08 % for empagliflozin 10 mg plus linagliptin 5 mg; -1,19 % for empagliflozin 25 mg plus linagliptin 5 mg; -0,70 % for linagliptin 5 mg).
In a double-blind trial in patients with inadequate glycemic control, 24-weeks treatment with both doses of empagliflozin plus linagliptin as add-on to metformin therapy provided statistically significant (p<0.0001) reductions in HbA1c (change from baseline of -1.08% for empagliflozin 10 mg plus linagliptin 5 mg, -1.19% for empagliflozin 25 mg plus linagliptin 5 mg, -0.70% for linagliptin
I et dobbeltblindet, kontrolleret klinisk studie blev 473 voksne på 60 år eller ældre randomiseret til at få en enkelt dosis ZOSTAVAX enten samtidig (N=237) eller ikke-samtidig med 23-valent pneumokok- polysaccharidvaccine (N=236).
In a double-blind, controlled clinical trial, 473 adults, 60 years of age or older, were randomised to receive a single dose of ZOSTAVAX either concomitantly (N=237), or nonconcomitantly with 23- valent pneumococcal polysaccharide vaccine (N=236).
I et dobbeltblindet, placebo-kontrolleret studie af patienter med ADPKD observeredes forhøjet (>3 x øvre normalgrænse [ULN]) ALT hos 4,4 % (42/958) af patienter på tolvaptan og 1,0 % (5/484) af patienter på placebo, mens forhøjet (>3xULN) AST observeredes hos 3,1 % (30/958) af patienter på tolvaptan og 0,8 % (4/484) af patienter på placebo.
In a double-blind, placebo-controlled trial in patients with ADPKD, elevation (>3 x upper limit of normal [ULN]) of ALT was observed in 4.4% (42/958) of patients on tolvaptan and 1.0% (5/484) of patients on placebo, while elevation (>3xULN) of AST was observed in 3.1% (30/958) of patients on tolvaptan and 0.8% (4/484) patients on placebo.
I et dobbeltblindet, placebokontrolleret, randomiseret klinisk studie blev ZOSTAVAX givet til 206 forsøgspersoner i alderen 60 år eller ældre, som var i kronisk/vedligeholdelsesbehandling med systemisk kortikosteroid med en daglig dosis svarende til 5 til 20 mg prednison i mindst 2 uger før indrullering og i 6 uger eller længere efter vaccination, for at vurdere ZOSTAVAX´ immunogenicitet og sikkerhedsprofil.
In a double-blind, placebo-controlled, randomised clinical trial, ZOSTAVAX was administered to 206 subjects 60 years of age or older who were receiving chronic/maintenance systemic corticosteroid therapy at a daily dose equivalent of 5 to 20 mg of prednisone for at least 2 weeks prior to enrollment, and 6 weeks or more following vaccination to assess the immunogenicity and safety profile of ZOSTAVAX.
I et dobbeltblindet, placebokontrolleret, randomiseret klinisk studie blev ZOSTAVAX givet til HIV- inficerede voksne (18 år eller ældre, medianalder på 49 år) med bevaret immunfunktion (CD4+ T-celletal≥ 200 celler/µl), der fik passende antiretroviral behandling.
In a double-blind, placebo-controlled randomised clinical trial, ZOSTAVAX was administered to HIV-infected adults (18 years of age or older; median age 49 years) on appropriate antiretroviral therapy with conserved immune function (CD4+ T cell count ≥ 200 cells/µL).
I et dobbeltblindt placebo- kontrolleret klinisk studie med voksne patienter med psoriasisartrit, modtog 184 af patienterne også en multivalent pneumokok polysakkarid vaccine i uge 4.
In a double blind, placebo controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.
I et dobbeltblindt, dobbel-dummy, parallel-gruppestudie til sammenligning af buprenorphin- ethanolopløsning med en ren agonist som aktiv kontrol blev 162 forsøgspersoner randomiseret til at få den sublinguale ethanolopløsning af buprenorphin ved 8 mg/dag (en dosis, som stort set svarer til en dosis buprenorphin/naloxon på 12 mg/dag), eller to relativt lave doser af den aktive kontrol, hvoraf den ene var lav nok til at tjene som et alternativ til placebo, i en indledende fase på 3 til 10 dage, en 16-ugers vedligeholdelsesfase og en 7-ugers afvænningsfase.
In a double-blind, double-dummy, parallel-group study comparing buprenorphine ethanolic solution to a full agonist active control, 162 subjects were randomized to receive the ethanolic sublingual solution of buprenorphine at 8 mg/day (a dose which is roughly comparable to a dose of 12 mg/day of buprenorphine/naloxone), or two relatively low doses of active control, one of which was low enough to serve as an alternative to placebo, during a 3 to10 day induction phase, a 16-week maintenance phase and a 7-week detoxification phase.
I et dobbeltblindt, placebo- kontrolleret klinisk studie med voksne patienter med psoriasisartrit, modtog 184 af patienterne også en multivalent pneumokok polysakkarid vaccine i uge 4.
In a double-blind, placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.
I et dobbeltblindt, placebo- kontrolleret, randomiseret klinisk studie med voksne patienter med psoriasisartrit, modtog 184 af patienterne også en multivalent pneumokok polysakkarid vaccine i uge 4.
In a double-blind, placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.
I et dobbeltblindt, placebo-kontrolleret klinisk studie med voksne patienter med psoriasisartrit, modtog 184 af patienterne også en multivalent pneumokok polysakkarid vaccine i uge 4.
In a double-blind, placebo- controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.
I et dobbeltblindt, randomiseret vehikel-kontrolleret studie, der blev udført hos diabetespatienter med retinopati, udviklede en signifikant højere procentdel af patienterne i vehikel-gruppen makulært ødem (16,7%) sammenlignet med de patienter, der blev behandlet med Nevanac (3,2%).
In 1 double-masked, randomised vehicle-controlled study, conducted in diabetic retinopathy patients, a significantly greater percentage of patients in the vehicle group developed macular oedema (16.7%) compared to patients treated with NEVANAC (3.2%).
I et efterfølgende forsøg blev 217 patienter, som var behandlingsnaive med hensyn til PDE5-inhibitorer, randomiseret til CIALIS 5 mg en gang dagligt versus placebo.
In a subsequent study, 217 patients who were treatment- naïve to PDE5 inhibitors were randomized to CIALIS 5 mg once a day vs. placebo.
I et efterfølgende åbent studie (SP824), et multi-center, multi-nationalt studie, blev tolerabilitet og effekt hos forsøgspersoner med idiopatisk Parkinsons sygdom undersøgt ved skifte, hen over natten, fra ropinirol, pramipexol eller cabergolin til rotigotin depotplaster.
In a subsequent open-label study (SP824), a multicenter, multinational study, the tolerability of overnight switching from ropinirole, pramipexole or cabergoline to rotigotine transdermal patch and its effect on symptoms in subjects with idiopathic Parkinson’s disease have been studied.
I et embryotoxicitetstudie foretaget på kaniner blev der observeret en højere incidens af kardiovaskulære- og knogle-deformationer, hvor hunkaninerne blev udsat for systemiske påvirkninger under den maksi- male kliniske eksponering (AUC).
In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximum clinical exposure (AUC).
I et enkelt humant studie blev Cubicin administreret intravenøst dagligt i 28 dage til en ammende mor i en dosis på 500 mg/dag, og prøver af patientens mælk blev samlet over en 24-timers periode på dag 27.
In a single human case study, Cubicin was intravenously administered daily for 28 days to a nursing mother at a dose of 500 mg/day, and samples of the patient’s breast milk were collected over a 24- hour period on day 27.
I et enkelt placebokontrolleret, klinisk fase III-studie med patienter med prostatacancer, der fik ADT (androgen deprivation therapy), blev der observeret en forskel mellem denosumab og placebogrupperne i hyppigheden af bivirkninger med grå stær (4,7 % denosumab, 1,2 % placebo).
In a single phase III placebo-controlled clinical trial in patients with prostate cancer receiving androgen deprivation therapy (ADT) an imbalance in cataract adverse events was observed (4.7% denosumab, 1.2% placebo).
I et enkelt tilfælde, hvor en patient tog 9.000 mg Tyverb, sås sinus-takykardi (patienten havde et ellers normalt ekg).
In a single case of a patient who took 9000 mg of Tyverb, sinus tachycardia (with otherwise normal ECG) was also observed.
I et enkelt-arms multicenterstudie fik 37 patienter med recidiveret elle kemoterapi-resistent lavmalignt eller follikulært B-celle NHL 375 mg/m2 MabThera som intravenøs infusion ugentligt i otte doser.
In a multi-centre, single-arm trial, 37 patients with relapsed or chemoresistant, low grade or follicular B cell NHL received 375 mg/m2 of MabThera as intravenous infusion weekly for eight doses.
I et enkelt-arms-studie (PBTC-022) blev18 børn med recidiverende eller progredierende høj-grads gliom, som ikke involverede hjernebroen (herunder 8 med glioblastom [WHO grad IV], 9 med anaplastisk astrocytom [grad III] og 1 med anaplastisk oligodendrogliom [grad III]), behandlet med bevacizumab (10 mg/kg) med 2 ugers mellemrum og derefter med bevacizumab i kombination med CPT-11 (125-350 mg/m²) hver anden uge indtil progression.
In a single-arm study (PBTC-022), 18 children with recurrent or progressive non-pontine high-grade glioma (including 8 with glioblastoma [WHO Grade IV], 9 with anaplastic astrocytoma [Grade III] and 1 with anaplastic oligodendroglioma [Grade III]) were treated with bevacizumab (10 mg/kg) two weeks apart and then with bevacizumab in combination with CPT-11 (125-350 mg/m²) once every two weeks until progression.
I et enkelt-dosis studie (6 personer per gruppe) blev middelværdi for plasma MPA AUC hos personer med svær, kronisk nedsat nyrefunktion (glomerulær filtrationsrate < 25 ml/min/1,73 m2) observeret til 28-75 % højere i forhold til middelværdierne hos normale, sunde personer eller personer med let nedsat nyrefunktion.
In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate < 25°mL/min/1.73°m2) were 28-75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment.
I et enkelt-dosis studie (6 personer per gruppe) blev middelværdi for plasma MPA-AUC hos personer med svær, kronisk nedsat nyrefunktion (glomerulær filtrationsrate < 25 ml/min/1,73 m2) observeret til 28-75 % højere i forhold til middelværdierne hos normale, sunde personer eller personer med let nedsat nyrefunktion.
In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate < 25 mL./min/1.73 m2) were 28 – 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment.
I et enkeltarms ekg-understudie (se pkt.
In a single arm ECG substudy (see section 5.2) using blinded manual ECG measurements
I et enkeltdosis ( 10 mg) Positron Emission Tomography (PET) studie hos raske forsøgspersoner bandt olanzapin til flere 5HT2A end til dopamin D2 receptorer.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy.
I et enkeltdosis (10 mg) Positron Emission Tomography (PET) studie hos raske forsøgspersoner bandt olanzapin til flere 5-HT2A end til dopamin D2 receptorer.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy.
I et enkeltdosis (10 mg) Positron Emission Tomography (PET) studie hos raske forsøgspersoner bandt olanzapin til flere 5-HT2A end til dopamin D2- receptorer.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy.
I et enkeltdosis (10 mg) Positron Emission Tomography (PET) studie hos raske forsøgspersoner bandt olanzapin til flere 5HT2A end til dopamin D2 receptorer.
In a single oral dose (10 mg) Positron Emission Ttomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy.
I et enkeltdosis (10 mg) Positron Emission Tomography (PET) studier hos raske forsøgspersoner bandt olanzapin til flere 5-HT2A end til dopamin D2-receptorer.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy.
I et enkeltdosis intramuskulær studie af olanzapin 5 mg, administreret 1 time før intramuskulær lorazepam 2 mg (metaboliseret ved glukuronidering), var farmakokinetikken af begge præparater uændret.
In a single dose intramuscular study of olanzapine 5 mg, administered 1 hour before intramuscular lorazepam 2 mg (metabolised by glucuronidation), the pharmacokinetics of both medicines were unchanged.
I et enkeltdosisstudie (6 personer per gruppe) blev middelværdi for plasma MPA-AUC hos personer med svær, kronisk nedsat nyrefunktion (glomerulær filtrationsrate < 25 ml/min/1,73 m2) observeret til 28-75 % højere i forhold til middelværdierne hos normale, sunde personer eller personer med let nedsat nyrefunktion.
In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate < 25mL/min/1.73 m2) were 28 – 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment.
I et enkeltdosisstudie med Galafold hos personer uden Fabrys sygdom, men med forskellige grader af nyreinsufficiens var eksponeringen øget med en faktor 4,3 hos personer med svært nedsat nyrefunktion (GFR < 30 ml/min/1,73 m2).
In a single dose study with Galafold in non-Fabry subjects with varying degrees of renal insufficiency, exposures were increased by 4.3-fold in subjects with severe renal impairment (GFR < 30 mL/min/1.73 m2).
I et enkeltdosisstudie resulterede eksponeringen over for silodosin (ubundet) hos patienter med let (n=8) og moderat nedsat nyrefunktion (n=8) i gennemsnit i en forhøjelse af Cmax (med 1,6 gange) og AUC (med 1,7 gange) i forhold til patienter med normal nyrefunktion (n=8).
In a single-dose study, exposure to silodosin (unbound) in subjects with mild (n=8) and moderate renal impairment (n=8) resulted, on average, in an increase of Cmax (1.6-fold) and AUC (1.7-fold) relative to subjects with normal renal function (n=8).
I et enkeltdosisstudie var palmifermins clearance cirka 30% lavere hos 8 raske forsøgspersoner i alderen 66-73 år efter en dosis på 90 mikrogram/kg end hos yngre forsøgspersoner (≤65 år) efter en dosis på 180 mikrogram/kg.
In a single dose study the clearance of palifermin was approximately 30% lower in 8 healthy subjects aged 66-73 years after a dose of 90 micrograms/kg than in younger subjects (≤ 65 years) after a dose of 180 micrograms/kg.
I et farmakoepidemiologisk forsøg var brug af pramipexol associeret med en øget risiko for hjertesvigt sammenlignet med ikke-brug af pramipexol (observeret risikoratio 1,86; 95 % CI 1,21-2,85).
In a pharmacoepidemiological study pramipexole use was associated with an increased risk of cardiac failure compared with non-use of pramipexole (observed risk ratio 1.86; 95% CI, 1.21- 2.85).
I et farmakoepidemiologisk forsøg var brug af pramipexol associeret med en øget risiko for hjertesvigt sammenlignet med ikke-brug af pramipexol (observeret risikoratio 1,86; 95% CI 1,21-2,85).
In a pharmacoepidemiological study pramipexole use was associated with an increased risk of cardiac failure compared with non-use of pramipexole (observed risk ratio 1.86; 95% CI, 1.21- 2.85).
I et farmakokinetisk enkeltdosisstudie med exenatid opløsning til injektion til 13 patienter med type 2- diabetes i alderen 12 til 16 år resulterede administration af exenatid (5 g) i et lettere reduceret gennemsnitligt AUC (16 % lavere) og Cmax (25 % lavere) sammenlignet med de værdier, der ses hos voksne.
In a single-dose pharmacokinetic study of immediate-release exenatide in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide (5 mcg) resulted in slightly lower mean AUC (16 % lower) and Cmax (25 % lower) compared to those observed in adults.
I et farmakokinetisk forsøg hos raske mandlige forsøgspersoner, der fik 150 mg [14C]-migalastathydrochlorid, blev 99 % af den radioaktivt mærkede dosis genfundet i plasma og bestod af uomdannet migalastat (77 %) og de tre hydrogenerede O-glukuronidkonjugerede metabolitter M1, M2 og M3 (13 %).
A pharmacokinetic trial in healthy male volunteers with 150 mg [14C]-migalastat HCl revealed that 99% of the radiolabeled dose recovered in plasma was comprised of unchanged migalastat (77%) and 3 dehydrogenated O- glucuronide conjugated metabolites, M1to M3 (13%).
I et farmakokinetisk forøg med celecoxib 200 mg indgivet 1 gang dagligt til raske frivillige forsøgspersoner med genotype CYP2C9*1/*1, CYP2C9*1/*3 eller CYP2C9*3/*3 er median Cmax og AUC0-24 for celecoxib på dag 7 henholdsvis ca. firedoblet og syvdoblet hos personer med genotype CYP2C9*3/*3 sammenlignet med andre genotyper.
In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median Cmax and AUC 0- 24 of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes.
I et farmakokinetisk forøg med celecoxib 200 mg indgivet 1 gang dagligt til raske frivillige forsøgspersoner med genotype CYP2C9*1/*1, CYP2C9*1/*3 eller CYP2C9*3/*3 er median Cmax og AUC0-24 for celecoxib på dag 7 henholdsvis ca. firedoblet og syvdoblet hos personer med genotype CYP2C9*3/*3 sammenlignet med andre genotyper.
In a pharmacokinetic study of celecoxib 400 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median Cmax and AUC 0- 24 of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes.
I et farmakokinetisk studie blev seks børn (i alderen 1 til 6 år) med medfødt FXIII A-subunit mangel eksponeret for en enkelt dosis NovoThirteen 35 IE/kg indgivet i.v.
In a pharmacokinetic trial 6 children (age 1 to less than 6 years old) with congenital FXIII A-subunit deficiency were exposed to one single i.v. dose of NovoThirteen 35 IU/kg.
I et farmakokinetisk studie med 7 patienter resulterede samtidig administration af docetaxel og den potente CYP3A4-hæmmer ketoconazol i et signifikant fald i docetaxel-clearance på 49 %.
In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.